echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > STAT3 protein degraders exhibit anticancer activity by increasing tumor sensitivity to PD-1 inhibitors

    STAT3 protein degraders exhibit anticancer activity by increasing tumor sensitivity to PD-1 inhibitors

    • Last Update: 2022-02-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Kymera announced the experimental results of KTX-201, a protein degrader targeting STAT3 protein


    STAT3 is a transcription factor that can be activated by different cytokine and growth factor receptors, possibly also by mutations in oncogenic fusion proteins and STAT3 itself


    ▲STAT3 has multiple roles in tumor survival and growth (Image source: Kymera's official website)

    Previously, Kymera found that KTX-201, a protein degrader targeting STAT3, as a single agent, can cause ALK-positive anaplastic large cell lymphoma (ALCL) in vitro and in vivo experiments, as well as NK/T with STAT3 mutants cell lymphoma, and increased growth arrest and cell death in ALK-negative ALCL cell lines


    Analysis of the gene expression profiles of KTX-201-treated tumors found that the expression of pro-inflammatory genes, as well as the expression of biomarkers of T-cell activation and M1 macrophage activation, were significantly increased compared with controls


    ▲KTX-201 changes the tumor microenvironment (Image source: Kymera official website)

    Moreover, when KTX-201 was combined with an anti-PD-1 antibody, it resulted in a 60% complete remission in a mouse model of solid tumors, and the animals gained immune memory and the growth of re-implanted tumors was inhibited


    ▲KTX-201 combined with anti-PD-1 antibody showed better anti-cancer activity (Image source: Kymera official website)

    Kymera pointed out that KTX-333, a potential "first-in-class" STAT3 protein degrader currently developed based on KTX-201, is expected to receive IND approval before the end of 2021, and will launch Phase 1 clinical trials in patients with hematological cancers and solid tumors


    References:

    [1] Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.